LXEO · Lexeo Therapeutics, Inc. · Financials
Market Cap
$348.70M
Shares
82.05M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$654K
FY2022
Net Income
-$100M
-1.7%
FY2025
Operating Margin
-9252.14%
FY2022
Diluted EPS
-$1.86
+39.8%
FY2025
Operating Cash Flow
-$98.56M
-21.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | — | — | — | $654K | |
| $66.64M | $63.8M | $74.09M | $53.13M | $49.16M | |
| $28.48M | $45.46M | $31.68M | $15.38M | $12M | |
| $293K | $268K | $304K | $271K | $120K | |
| $95.12M | $109.26M | $105.77M | $68.51M | $61.16M | |
| -$95.12M | -$109.26M | -$105.77M | -$68.51M | -$60.51M | |
| — | — | — | — | -9252.14% | |
| -$94.82M | -$108.99M | -$105.46M | -$68.24M | -$60.39M | |
| $73K | $95K | $137K | $205K | $91K | |
| $7.98M | $6.13M | $7.56M | $2.87M | $1.33M | |
| $7.85M | $9.3M | $7.43M | $2.12M | $1.23M | |
| -$86.97M | -$99.67M | -$98.44M | -$66.39M | -$59.28M | |
| — | $0 | $0 | — | — | |
| -$87.3M | -$100M | -$98.33M | -$66.39M | -$59.28M | |
| — | — | — | — | -9063.76% | |
| -$87.55M | -$99.67M | -$98.44M | -$66.39M | — | |
| USD/shares | -$0.82 | -$1.86 | -$3.09 | -$12.40 | -$36.36 |
| USD/shares | -$0.82 | -$1.86 | -$3.09 | -$12.40 | -$36.36 |
| shares | — | 53.65M | 31.79M | 5.35M | 1.63M |
| shares | — | 53.65M | 31.79M | 5.35M | 1.63M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.98×
EV/EBIT
—
Peer median 9.22×
P/E (TTM)
—
Peer median 11.89×
Peer medians compare against the 320 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
1907108
CUSIP
52886X107
13F (30d)
55 filings
55 filers
Visit website
Investor relations